Sermorelin / Ipamorelin Blend
A research peptide blend combining Sermorelin (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist), studied for synergistic amplification of growth hormone release with complementary cardiovascular, skeletal, and metabolic effects.
This blend combines Sermorelin, the biologically active N-terminal 29-amino-acid fragment of GHRH, with Ipamorelin, the most selective growth hormone secretagogue receptor agonist currently characterized. When combined, these peptides act synergistically through complementary pituitary receptor pathways to amplify growth hormone release while maintaining physiological feedback regulation.
Overview
Sermorelin is a GHRH analogue designed to preserve the positive effects of natural GHRH on pituitary somatotrophs. Ipamorelin is the most specific and selective ghrelin receptor agonist known, activating GHS-R1a without significantly affecting cortisol, prolactin, or ACTH levels at therapeutic doses. This selectivity distinguishes the sermorelin/ipamorelin combination from blends using less selective GHRPs such as GHRP-6 or GHRP-2. The synergistic GH release achieved by this combination maximizes downstream benefits including effects on muscle growth, brain health, cardiovascular function, and metabolism.
Mechanism of Action
Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, activating adenylyl cyclase and the cAMP/PKA signaling cascade to drive GH gene transcription and secretion. Ipamorelin activates GHS-R1a, engaging the PLC/IP3/PKC pathway. The convergent activation of these two distinct receptor systems on the same somatotroph cell produces synergistic GH pulse amplification. Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly stimulate cortisol, prolactin, or appetite at GH-releasing doses, making this blend the most selective dual-pathway GH secretagogue combination available.
Reconstitution Calculator
Sermorelin / Ipamorelin Blend
This blend combines Sermorelin, the biologically active N-terminal 29-amino-acid
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Cardiovascular Effects
Research in swine models demonstrates that sermorelin (as a GHRH agonist) reduces cardiomyocyte cell death, improves healing following cardiac injury, promotes collateral blood vessel growth, and reduces inflammation. Bagno et al. (2015) showed that GHRH agonists reduce myocardial infarct scar in subacute ischemic cardiomyopathy. Kanashiro-Takeuchi et al. (2015) demonstrated a therapeutic approach to heart failure based on targeting the GHRH receptor. A form of the ghrelin receptor has also been identified in cardiac tissue, and administration of ghrelin analogues has been shown to reduce arrhythmia risk and improve post-injury cardiac healing, as reviewed by Tokudome et al. (2019).
Central Nervous System and Sleep
Sermorelin has demonstrated benefits for the central nervous system in animal models. Tang et al. (2017) investigated interactions between GHRH and GABA-A receptors in the brain, suggesting roles in neuronal regulation. Research has also linked GHRH signaling to sleep quality improvement through modulation of slow-wave sleep architecture.
Bone Health
Ipamorelin has shown significant effects on bone metabolism. Andersen et al. (2001) demonstrated that ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats. Svensson et al. (2000) showed that ipamorelin and GHRP-6 increase bone mineral content in adult female rats, suggesting potential applications in osteoporosis research.
Metabolic and Gastrointestinal Effects
Adeghate & Ponery (2004) investigated the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats, indicating potential roles in glucose homeostasis. Beck et al. (2014) conducted a prospective, randomized, controlled study of ipamorelin for management of postoperative ileus in bowel resection patients, demonstrating its prokinetic properties.
Safety Profile
This blend benefits from the favorable safety profiles of both components. Sermorelin has been used clinically with adverse effects generally limited to injection site reactions, flushing, and headache. Ipamorelin is the most selective GH secretagogue, notable for not significantly increasing cortisol, prolactin, or ACTH at GH-releasing doses, which reduces the side effect burden compared to other GHRP-based combinations. The blend preserves physiological GH pulsatility and somatostatin-mediated negative feedback. No significant adverse effects have been reported in animal studies using the combination.
Pharmacokinetic Profile
Sermorelin / Ipamorelin Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
What to Expect
What to Expect
Rapid onset expected; half-life of Sermorelin: ~10-20 min; Ipamorelin: ~2 hours indicates fast-acting pharmacokinetics
Due to short half-life (Sermorelin: ~10-20 min; Ipamorelin: ~2 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Injection site reactions reported
Frequently Asked Questions
References (12)
- [10]Donato et al — Growth hormone-releasing hormone/growth hormone secretagogue combination therapy: an updated review Endocrine (2023)
- [11]Sinha et al — Revisiting the role of growth hormone secretagogues in age-related sarcopenia and frailty Aging Cell (2023)
- [12]Broglio et al — Long-term cardiovascular effects of growth hormone secretagogues: clinical perspectives Frontiers in Endocrinology (2022)
- [1]Bagno LL et al Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy J Am Heart Assoc (2015)
- [7]Adeghate E & Ponery AS Mechanism of ipamorelin-evoked insulin release from the pancreas Neuro Endocrinol Lett (2004)
- [2]Kanashiro-Takeuchi RM et al New therapeutic approach to heart failure due to myocardial infarction based on targeting GHRH receptor Oncotarget (2015)
- [4]Tang S et al Interactions between GHRH and GABAARs in the brains of patients with epilepsy Sci Rep (2017)
- [5]Andersen NB et al Ipamorelin counteracts glucocorticoid-induced decrease in bone formation Growth Horm IGF Res (2001)
- [6]Svensson J et al Ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats J Endocrinol (2000)
- [8]Beck DE et al Prospective, randomized, controlled study of ipamorelin for postoperative ileus Int J Colorectal Dis (2014)
- [9]Walker RF Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging (2006)
- [3]
Sermorelin / GHRP-6 / GHRP-2 Blend
A triple-peptide research blend combining Sermorelin (a GHRH analogue) with GHRP-6 and GHRP-2 (both ghrelin receptor agonists), studied for synergistic GH axis stimulation and complementary secondary effects on neuroprotection, wound healing, and immune function.
Sermorelin
Sermorelin is a synthetic 29-amino acid analogue of growth hormone-releasing hormone (GHRH) used to assess and stimulate natural growth hormone secretion. It is researched for cardiac repair, bone density, sleep regulation, epilepsy, and age-related GH decline.